Government funds heavily invested, private capital "rushing in": Why is biomanufacturing so hot?

BiomanufacturingNow transitioning from the "frontier track" to the first year of industrial explosion.

From 2025 to 2026, this sector entered a "funding boom." According to incomplete statistics, in 2025, the largest single financing deal in China's bio-manufacturing sector reached 5 billion yuan, spanning Series A through E rounds and follow-on funding, with government funds, private capital, and industrial investors collaborating.

From breakthroughs in the foundational technologies of synthetic biology to large-scale implementation across food, pharmaceuticals, materials, and cosmetics, capital and policy are creating a powerful synergy: local government industrial funds are aggressively leading investments, national key projects are being launched consecutively, private capital is competing to participate, and corporate funding rounds continue to reach new heights.

Against a backdrop of diversified growth across niche sectors, a dynamic wave of industrial expansion is unfolding—accelerating the industry's transition from "technology exploration" to "scalable industrialization." Biomanufacturing has emerged as one of today's most promising strategic emerging industries.

[ Local Government Funds Heavily Positioned ]

Biomanufacturing becomes a critical battleground for regional industrial development

2026, 4, 15ShenzhenThe Science and Technology Bureau, along with three other departments, jointly issued the "Several Measures for Shenzhen to Promote High-Quality Development of the Bio-Manufacturing Industry by Leading Synthetic Biology Innovation," establishingOver 100 billion yuanThe industrial guidance fund system supports "20+8" industry funds in investing in biomanufacturing projects and actively connects with national-level funds such as the Greater Bay Area Venture Capital Guidance Fund and the Social Security Greater Bay Area Science and Technology Innovation Fund.

This is just one piece of the national puzzle.

The 15th Five-Year Plan identifies biomanufacturing as one of the six future industries.Local government industrial funds have become the "stabilizing anchor" and "lead investor" in bio-manufacturing financing.

Strategies vary by region:HeilongjiangImplement policies to provide subsidies of up to 20% of fixed asset investment for new industrial-scale bio-manufacturing projects.5000 ten thousand yuan；Beijing Economic-Technological Development AreaPublish 12 measures, with a maximum support of up to3000 ten thousand yuancovering the entire chain, including pilot platforms and concept validation;AnhuiEstablish30 hundred million yuanA central-local cooperative bio-manufacturing industry fund, and the designation of a provincial pilot zone for future industries...

The logic of capital is shifting—government funds are no longer pursuing financial returns alone, but instead"Industry Implementation""Cluster Cultivation"As a core KPI. This means competition among bio-manufacturing companies has evolved from a battle over "technology pathways" to a contest over "industrial ecosystems."

Review of key financing events from 2025 to 2026, covering 4 months. Financing was widely distributed across synthetic biology, bio-based materials, AI + life sciences, biopharmaceuticals, bio-instruments, microbiome, and agricultural biotechnology. Synthetic biology, bio-based materials, and AI-driven biomanufacturing emerged as top investment priorities.

The biomanufacturing sector is showing signs of "Full-chain explosion, concentration at the top, and scenario deploymentdistinctive features of.

Platform leader. Redlin BiobyOver 5 billion yuan in Series C fundingBecome the 2025 Year's Top Funded Company. Its "AI + Biomanufacturing" platform covers multiple categories including peptides, sugars, and nucleotides, and has achieved scaled mass production.Yikeli BioComplete 4$5 billion Series D financingfurther solidifying its position as a leading platform company in the field of biocatalysis.

These two companies do not rely on a single product; instead, they leverage their technology platforms to enable multi-category development. This approach offers strong risk resilience and high capital valuation premiums.

The medical aesthetics and efficacy ingredient sectors are fiercely competitive. In the field of recombinant collagen, PolySource Bio (Series B+ funding exceeding 100 million yuan) and Jinbo Bio (1.65 yuan capital increase).Successive funding rounds reflect the market narrative of "collagen replacing hyaluronic acid."Natural flavorings and active ingredients，Inocell (nearly 1.5 billion yuan in Series A), Ruifen Bio (over 100 million yuan in Series C)All have gained capital recognition in their respective niche markets.

Bio-based materials enter the industrialization validation phase. Zhongke Guosheng (¥2 billion, A+ round) and Yixi Biology (nearly ¥2 billion, A round).Secured strong capital backing in two high-barrier sectors: bio-based material FDCA and human milk oligosaccharides (HMO). Zhongke Guosheng is the global pioneer in developing the HMF bio-based platform compound and its derivative value chain. Its core product portfolio spans the full industrial chain from HMF to FDCA, with 100-ton and 10,000-ton production facilities located in Lishui, Zhejiang, and Taixing, Jiangsu. The company's proprietary "SMART" catalytic system combined with a "short-process" production approach enables fully continuous manufacturing of HMF and FDCA, significantly reducing product costs.

In 2026, capital's "rational frenzy" continues, with even sharper focus on companies possessing unique technology platforms and green alternative models.Micro-element SynthesisLeading the start of the year with a 3 billion yuan Series A+ round, its methanol biomanufacturing pathway opens new possibilities for industrializing non-food carbon sources.Tianwu Technology(2 billion yuan, Series A+): Leveraging its AI-powered protein design platform, it is reshaping the "operating system" of biomanufacturing.

This indicates that significant capital is flowing into various segments of bio-manufacturing, moving the industry from a "frontier concept" to the critical phase of "realizing production value."

Heavy capital investment, policy support, capacity surge, and technological iteration—the industrialization of biomanufacturing has arrived. 2026 is the pivotal year for biomanufacturing to transition from "technology narratives" to "industrial implementation."

When you're at the forefront, clarity of direction is more critical than ever.The 2026 BIO-TECH Manufacturing Industry Expo will be held grandly in Shanghai from 8/27-28.This exhibition is organized by Yimao Medical. Invited guests will be present on-site, including:2000+Attendee,150+ Speaker,50+Premium exhibitors, featuring "Exhibitions - Products - Conferences - PartnershipsFour core modules focused on "breakthroughs in fundamental research and cross-sector industrialization," establishing a benchmark event for the entire bio-manufacturing value chain.